Page last updated: 2024-12-08
oncocalyxone a
Description
oncocalyxone A: a 1,4-anthracenedione isolated from Auxemma oncocalyx (Boraginaceae) that has been shown to be cytotoxic to tumor cells in vitro [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Oncocalyx | genus | [no description available] | Loranthaceae | The showy mistletoe plant family of the order Santalales, subclass Rosidae, class Magnoliopsida. This includes parasitic tropical plants with haustoria connecting to the hosts. The leaves are opposite and thick. The flowers (4-7) have both calyx and corolla. The fruit is a berry with one seed.[MeSH] |
Cross-References
Synonyms (7)
| Synonym |
|---|
| nsc720597 |
| NCI60_041320 |
| rel-8.alpha.hydroxy-5-hydroxymethyl-8a.beta.-methyl-2-methoxy-7,8a,9-tetrahydro-1,4-anthracenedione |
| nsc-720597 |
| oncocalyxone a |
| (5r,10as)-5-hydroxy-8-(hydroxymethyl)-3-methoxy-10a-methyl-6,10-dihydro-5h-anthracene-1,4-dione |
| CHEMBL1975567 |
Research Excerpts
Overview
Oncocalyxone A (oncoA) is a quinone extracted from the Cordia oncocalyX plant.
Effects
Oncocalyxone A has many pharmaceutical uses such as: antitumor, analgesic, antioxidant and causative of inhibition of platelet activation. OncoA has a concentration-dependent anti-platelet activity.
| Excerpt | Reference | Relevance |
|---|
| "Oncocalyxone A (OncoA) has a concentration-dependent anti-platelet activity. " | ( Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein.
Chudzinski-Tavassi, AM; de Lemos, TL; de Sousa, CM; do Nascimento, NR; Ferreira, MA; Pessoa, OD; Schattner, M; Ventura, JS, 2008) | 3.23 |
| "Oncocalyxone A (Onco A) has many pharmaceutical uses such as: antitumor, analgesic, antioxidant and causative of inhibition of platelet activation." | ( Study of molecular structure, vibrational, electronic and NMR spectra of oncocalyxone A using DFT and quantum chemical calculations.
Ayala, AP; Fechine, PB; Honorato, SB; Joshi, BD; Pessoa, OD; Srivastava, A; Tandon, P, 2013) | 1.34 |
| "Oncocalyxone A (OncoA) has a concentration-dependent anti-platelet activity. " | ( Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein.
Chudzinski-Tavassi, AM; de Lemos, TL; de Sousa, CM; do Nascimento, NR; Ferreira, MA; Pessoa, OD; Schattner, M; Ventura, JS, 2008) | 3.23 |
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 5 (38.46) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.09
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.09 (24.57) | | Research Supply Index | 2.71 (2.92) | | Research Growth Index | 4.80 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.14%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (92.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |